Cart
sales@molnova.com
Senexin-A
CAS No. 1366002-50-7
Senexin-A( Senexin A )
Catalog No. M11512 CAS No. 1366002-50-7
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 5MG | 67 | In Stock |
|
| 10MG | 96 | In Stock |
|
| 25MG | 187 | In Stock |
|
| 50MG | 333 | In Stock |
|
| 100MG | 475 | In Stock |
|
| 200MG | 644 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSenexin-A
-
NoteResearch use only, not for human use.
-
Brief DescriptionA selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
-
DescriptionA selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively; inhibits only p21-induced transcription but not other biological effects of p21, inhibits β-catenin-dependent transcription in HCT116 colon carcinoma cells; suppresses damage-induced tumor-promoting paracrine activities of tumor cells and normal fibroblasts and reverses the increase in tumor engraftment and serum mitogenic activity in mice pretreated with doxorubicin.
-
In Vitro——
-
In Vivo——
-
SynonymsSenexin A
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1366002-50-7
-
Formula Weight274.32
-
Molecular FormulaC17H14N4
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥100 mg/mL
-
SMILESN#CC1=CC2=C(NCCC3=CC=CC=C3)N=CN=C2C=C1
-
Chemical Name6-Quinazolinecarbonitrile, 4-[(2-phenylethyl)amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Porter DC, et al. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804.
2. McDermott MS, et al. Oncotarget. 2017 Feb 21;8(8):12558-12575.
molnova catalog
related products
-
CK7
CK7, a?Cdk2/9?inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
-
ML141
ML141 is a potent, selective and reversible non-competitive inhibitor of Rho family GTPase cdc42 with IC50 of 200 nM.
